Background: Long-term quality of life (QoL) after liver resection is becoming increasingly important, as improvements in operative methods and perioperative care have decreased morbidity and mortality rates. In this study, postoperative QoL after resection of benign or malignant liver tumours was evaluated.
Introduction
Advances in surgical technique, anaesthesiology and perioperative care have resulted in a decrease in postoperative mortality and morbidity after major hepatic surgery in specialized liver units 1, 2 . As a result, the indications for, and extent of liver resections are being expanded 3 -5 , with patient-tailored medicine and individualized resection strategies becoming increasingly important 6 . As a result of these developments, including advances in adjuvant therapies, survival rates following liver resection for colorectal metastases, hepatocellular carcinoma and cholangiocarcinoma have increased in recent decades 7 -11 . With reduced morbidity and increased survival after hepatectomy, quality of life (QoL) becomes a leading issue and, particularly from a patient's point of view, as important as disease-free or overall survival 12 -14 . The term 'quality of life' is being used increasingly, and tries to capture aspects of patient care and therapeutic goals previously not taken into account. QoL is subjective, multidimensional and dynamic over time, and continuously fluctuates as it responds to life events. It includes a variety of domains and parameters, including physical, functional, social and emotional well-being. Interestingly, the sum of these components does not necessarily equal the subjective assessment of overall QoL 15 . Although patients with malignant diseases may more often complain about physical problems such as pain and restriction in physical activities than healthy individuals, they may nevertheless report a relatively good overall QoL. For health professionals and bystanders, there seems to be a discrepancy between reported health-related problems and the patient's personal judgement of overall health status.
A previous retrospective study 16 evaluating postoperative QoL in patients undergoing liver resection for benign or malignant liver tumours did not show a correlation between poor prognosis and postoperative QoL, a finding that may come as a surprise, considering the nature of certain illnesses. However, the retrospective design of the study and missing preoperative baseline QoL scores may Values in parentheses are percentages.
Life Questionnaire C30 (QLQ-C30), version 3.0. This cancer-specific QoL instrument was used originally in clinical trials involving patients with cancer. It contains five functional scales, including physical, role, social, emotional and cognitive functions, as well as questions specifically aimed at checking for symptoms often reported by patients with cancer (fatigue, nausea/vomiting, pain, dyspnoea, insomnia, loss of appetite, constipation/diarrhoea). The financial impact of the disease on the patient is also taken into account. The questionnaire consists of 30 items, 28 of which have a four-point scale; two items have a seven-point scale for the overall QoL and health measure 18 . In addition, the QLQ-LMC21 was used. This questionnaire consists of 21 items, each of which has a four-point scale. The QLQ-LMC21 was initially designed to be used for patients with colorectal liver metastases because the general EORTC QLQ-C30 did not adequately address problems specifically associated with hepatic metastases. Question categories include items on food intake, weight loss, pain, jaundice, fatigue, social problems, anxiety, and the influence of the disease on sexual activity 19 .
Ethical considerations
Ethical approval was obtained from the University of Berne ethical committee (institutional protocol number KEK 18/08). The study was registered at ClinicalTrials.gov (NCT00681499). Written permission was obtained from all study participants. All eligible patients were given details of the study, including contact information for the researcher. Patients were informed about the study, and were guaranteed anonymity and confidentiality with regard to the information given to the researcher. A licensing agreement was obtained from the EORTC for use of QLQ-C30, version 3.0, and the QLQ-LMC21.
Statistical analysis
Primary and secondary outcomes were analysed based on multiply imputed data using repeated-measures mixed-effects linear regression models, adjusted for the baseline characteristics age, sex, jaundice, pruritus, weight loss, nausea, abdominal pain, lack of appetite, ASA fitness grade (considered as a continuous variable), diabetes, cardiovascular disorders, pulmonary disorders and other disorders. Differences in scores between groups are presented with 95 per cent confidence intervals. Missing score data were accounted for by multiple imputation, assuming data to be missing at random. Each score (global health status, physical function, emotional function, fatigue and pain) was imputed separately by linear regression methods, based on the tumour type and the following variables: patient age at inclusion, duration of hospital stay, ASA grade (all continuous), number of resected liver segments, death, relapse, sex, jaundice, pruritus, weight loss, nausea, abdominal pain, lack of appetite, diabetes, cardiovascular disorders, pulmonary disorders, other disorders, (neo)adjuvant chemotherapy, adjuvant radiotherapy, superficial infection, biloma, pneumonia and other complications (all categorical). The number of liver segments was missing for two patients, and duration of hospital stay for four patients. These were imputed along with global health status. Owing to the lack of a monotone missing data pattern, multiple imputation by chained equation was performed. In total, 20 imputed data sets were generated and analysed as described above using Rubin's rules 20 . Sensitivity analyses were based on complete data, disregarding multiple imputation. All analyses were performed in Stata ® release 13 (StataCorp, College Station, Texas, USA).
Results
A total of 196 patients undergoing liver resection between June 2007 and January 2013 were initially included in the study. Eight patients were subsequently excluded as unexpected intraoperative findings resulted in no liver resection being performed. Thus 130 patients with malignant disease and 58 with benign pathology were available for final analysis (Tables 1 and 2 ). Patients with benign tumours were more often women (P = 0⋅007) and younger (P < 0⋅001) than patients with malignant tumours. Patients with benign disease presented more frequently with nausea, abdominal pain and a lower ASA fitness grade (all P < 0⋅001). There were no statistically significant differences in other baseline characteristics between the groups ( Table 1) . The amount of liver tissue removed was no different between the groups; 53 per cent of patients with benign tumours required major liver surgery compared with 64⋅6 per cent of those with malignant tumours (P = 0⋅223). Duration of hospital stay was longer for patients with malignant disease (P < 0⋅001) ( Table 3 ).
The completeness of the EORTC questionnaires was analysed before surgery and after 1, 3, 6 and 12 months (data not shown). The completeness was 97⋅7 and 99 per cent before surgery in the maligant and benign groups respectively; at 12 months after surgery, it dropped to 69⋅1 per cent in patients with malignant disease, whereas it remained high at 97 per cent in patients with benign disease. Dropout in the early stages was mainly due to unwillingness to continue taking part (filling in the 2 questionnaires was 'too tedious'). At later time points other factors, such as death or loss to follow-up, played a more important role. Eight patients (6⋅2 per cent) with malignant tumours died within the 12-month follow-up For analysis of the QLQ-C30 and QLQ-LMC21 results, the individual parameters were summarized in five categories: global health status, physical function, emotional function, fatigue and pain. Global health status (as measured by the QLQ-C30) was equally low in patients with malignant and those with benign tumours in the preoperative setting, and dropped similarly at 1 month after liver resection. Global health status improved over time in both groups, with the score gradually increasing again at 3, 6 and 12 months after surgery. However, patients with benign disease had better global health status after 3, 6 and 12 months than those with malignant tumours (P < 0⋅001, P = 0⋅002 and P = 0⋅006 respectively). In both groups, global health status was better 12 months after surgery compared with preoperative values (P < 0⋅001 and P = 0⋅042 for patients with benign and malignant disease respectively) (Fig. 1a) . Patients with recurrent disease did not present with worse global health status (P = 0⋅961).
Similar results were found in the QLQ-C30 category physical function. Patients in both groups recovered physical function after an initial drop 1 month after surgery. Those with benign disease had better physical function scores at 3, 6 and 12 months than patients with malignant diseases (P = 0⋅011, P = 0⋅025 and P = 0⋅041) (Fig. 1b) . Emotional function according to the QLQ-C30 score was similar in both groups at baseline. Unlike the global health and physical function scores, there was no initial decrease in emotional function score after surgery. The emotional function score increased continuously up to 12 months after liver resection, and was identical in the two groups at 12 months. At 3 and 6 months, patients with benign disease had slightly better emotional function scores than those with malignant disease (P = 0⋅005 and P = 0⋅019) (Fig. 1c) .
Fatigue as a symptom was identical in both groups at baseline. Fatigue scores increased to a similar extent 1 month after surgery in all patients, and subsequently decreased to preoperative values in patients with malignant tumours. However, in those with benign tumours, fatigue was less pronounced at 3, 6 and 12 months than in patients with malignant disease (P = 0⋅001, P = 0⋅002 and P = 0⋅002) but also reduced compared with baseline (Fig. 1d) . Mean scores for pain were identical in both groups at baseline, 1, 6 and 12 months. One month after liver resection, pain scores were still increased compared with preoperative values in all patients. Those with malignant tumours had a higher pain score at 3 months after surgery than patients who underwent liver resection for benign tumours (P = 0⋅005) (Fig. 1e) .
Discussion
This study evaluated QoL in patients undergoing liver resection for benign or malignant tumours over a long time interval. Liver resection was found to be safe, with acceptable morbidity and a low mortality rate, as reported previously 1 . As might be expected, self-reported overall QoL, as measured by the global health status score, declined in the first month after surgery in both groups. It is essential that patients are informed about this before surgery, and given reassurance that QoL improves for the majority after the first month. By 3 months after surgery, QoL had already increased substantially and continued to do so during 12 months of follow-up. For patients with benign pathologies, this finding is in line with the high rate of symptom relief after liver resection reported previously 21 . In line with observations in many specialized liver units worldwide 22, 23 , minimally invasive liver resections are increasingly becoming the standard in the present authors' unit, now making up the majority of hepatic resections. However, during the study interval, patients still mainly underwent open hepatic surgery. The number of laparoscopic liver resections was too small for statistical analysis, but the decrease in self-reported QoL at 1 month after surgery may be expected to be less in patients undergoing laparoscopic resection 24 .
Some patients who did not complete the questionnaire 1 month after operation were still in hospital at that time. It seems reasonable to assume that their self-reported overall QoL might have been worse than that reported by patients who did answer the questionnaires at this time point. However, patients with postoperative complications who answered the questionnaires at 1 month had QoL scores not statistically different from those with an uncomplicated postoperative course. This contrasts with what treating surgeons and physicians might expect. However, as shown by others 25, 26 , self-reported QoL remains subjective, taking into account a multitude of factors. These are not based solely on measurable factors such as disease entity (malignant versus benign) or the presence or absence of physical restrictions and limitations.
Interestingly, preoperative (baseline) QoL was very similar in the two groups, as were some of the main parameters analysed by the QLQ-C30 and QLQ-LCM21 (physical function, emotional function, fatigue and pain). This too seems counterintuitive, as one might expect patients with malignant diagnoses to fare worse. However, these findings may in part be explained by the fact that patients with benign tumours more frequently reported nausea and abdominal pain at their first consultation. Another contributing factor may be the patient's general attitude and expectations towards the planned surgical intervention in case of a malignant diagnosis. Patients with malignant disease will be aware that surgery may be the only potentially long-term curative treatment strategy. Knowing that they qualify for surgery may therefore result in improved self-reported overall QoL 27 .
The findings of this study are limited by its single-centre design, restricting generalization of the results. In addition, patients with malignant disease who did not respond to the survey may have had poor QoL, potentially biasing the results presented. Finally, the sample size for this study was calculated for the overall self-reported QoL but not for each subanalysis undertaken.
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